Patients with chronic rhinosinusitis (CRS) with nasal polyps reported significantly reduced anosmia prevalence when given dupilumab vs placebo.
Dupilumab treatment was associated with significantly reduced anosmia prevalence among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and smell impairment. Findings were reported at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and are published in The Journal of Allergy and Clinical Immunology.
It is estimated that 60% to 80% of patients with CRSwNP have olfactory dysfunction, which has been linked with physical and social alterations that impair quality of life.
Prior results of the LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52 phase 3 trials showed that dupilumab treatment improved sense of smell in patients with CRSwNP, and researchers sought to further examine olfactory outcomes in patients of the 52-week trial.
They conducted a post hoc analysis of SINUS-52, in which patients were randomly assigned to dupilumab 300 mg every 2 weeks for 52 weeks (n = 136) or placebo (n = 146).
Patients with baseline smell impairment were analyzed, which was identified by a loss of smell score greater than or equal to 1 (mild), a University of Pennsylvania Smell Identification Test (UPSIT) score of greater than or equal to 34 for women and greater than or equal to 33 for men, and a very mild or greater problem in decreased sense of smell/taste identified by the 22-item sino-nasal outcome test (SNOT-22).
“Change from baseline in nasal polyp score (NPS, 0-8)/nasal congestion (NC, 0-3)/SNOT-22 (0-110) was reported in patients with anosmic (UPSIT 0-18) and normosmic (UPSIT > 34/ > 33 [women/men]) CRSwNP at week 52,” noted researchers.
At baseline, prevalence of anosmia was reported in 81.6% and 77.4% of patients with CRSwNP given dupilumab and placebo, respectively. Findings at week 52 showed a marked reduction in the proportion of patients with anosmia treated with dupilumab (29.2%), with a further 11.5% of patients reporting a normal sense of smell (normosmia).
Conversely, prevalence of anosmia was largely unchanged among patients with CRSwNP treated with placebo (76.8%), with none reporting normosmia.
Greater mean (SD) changes from baseline in NPS/NC/SNOT-22 were also observed in patients reporting normosmia vs anosmia with dupilumab at week 52:
“Greater improvements in NPS, NC and SNOT-22 were observed in dupilumab-treated patients reporting better olfactory outcomes at week 52, which may have contributed to their improved olfaction,” noted researchers.
Reference
Mullol J, Hopkins C, Fokkens W, et al. Dupilumab leads to reduction of anosmia in patients with severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. Published online February 1, 2022. doi:10.1016/j.jaci.2021.12.486
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More